LifeSphere® MultiVigilance (前称 ARISg/ARISc)

- 满足中国监管合规要求的药物警戒数据库

Download Whitepaper

By clicking ‘Submit’ button, you are agreeing to opt-in to communications from ArisGlobal and use of the above information for ArisGlobal products, news & updates.

Note: You can unsubscribe to email communication from ArisGlobal any time.

China is the second largest pharmaceutical market in the world after the US and is forecasted to grow at an annual growth rate of 9.1%, to $167 billion by 2020.

With regulatory environment aligning with of global standards, the country aims to promote innovation, simplify drug development processes and to enhance the efficacy, quality and safety of the drugs approved.

The paper explores how regulatory reforms in China is shaping the Pharmacovigilance Industry.

Download this whitepaper to learn about LifeSphere® Safety MultiVigilance:

  • The only pharmacovigilance and safety compliance solution with an in-built Chinese interface on the market
  • Single global database supporting the drug safety requirements of multiple regions with multilingual capabilities, including English, Chinese, Japanese and French
  • Accurately generates any kind of report such as line listings for easy evaluation of the risk-benefit profile including Chinese line listings